Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialYung‐Jue Bang, Yoon‐Koo Kang, Eric Van Cutsem et al.|The Lancet|2010Cited by 7.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Shukui Qin, Jia Chen et al.|Journal of Clinical Oncology|2020Cited by 1.2k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021Feng‐Hua Wang, Rui‐Hua Xu, Xiao‐Tian Zhang et al.|Cancer Communications|2021Cited by 657
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Jiafu Ji, Liang Han et al.|The Lancet Oncology|2021Cited by 436
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)Feng‐Hua Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Journal of Clinical Oncology|2021Cited by 350